Precision BioSciences, Inc. (DTIL)

Market Cap	59.97M
Revenue (ttm)	75.10M
Net Income (ttm)	8.62M
Shares Out	7.23M
EPS (ttm)	1.15
PE Ratio	5.40
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	132,536
Open	8.49
Previous Close	9.02
Day's Range	8.02 - 8.95
52-Week Range	7.97 - 19.43
Beta	1.69
Analysts	Strong Buy
Price Target	39.50 (+376.48%)
Earnings Date	Nov 4, 2024

About DTIL

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surfac...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 28, 2019
• Employees: 109
• Stock Exchange: NASDAQ
• Ticker Symbol: DTIL
• Website: https://www.precisionbiosciences.com

Financial Performance

In 2023, Precision BioSciences's revenue was $48.73 million, an increase of 94.15% compared to the previous year's $25.10 million. Losses were -$61.32 million, -45.07% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for DTIL stock is "Strong Buy." The 12-month stock price forecast is $39.5, which is an increase of 376.48% from the latest price.

Price Target

$39.5

(376.48% upside)

Analyst Consensus: Strong Buy